Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 7, 2004, Pages 862-867

  Langdon, Grant ^a,b   Wilkins, J J ^a   Smith, P J ^a   McIlleron, H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Patients; Pharmacokinetics; Rifapentine; Tuberculosis

Indexed keywords

25 DEACETYLRIFAPENTINE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAPENTINE;

ADULT; APPETITE DISORDER; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; NAUSEA; PRIORITY JOURNAL; RASH; SOUTH AFRICA; STOMACH PAIN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 3142778432     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Aventis Pharmaceuticals. Priftin® (rifapentine) 150 mg tablets, Prescribing Information: Kansas City, MO: Aventis, August 2000.
2. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002; 360: 528-534.
3. Tam C M, Chan S L, Kam K M, Goodall R L, Mitchison D A. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 2002; 6: 3-10.
4. Tam C M, Chan S L, Kam K M, et al. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis 2000; 4: 262-267.
5. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999 29; 353: 1843-1847.
6. Tam C M, Chan S L, Lam C W, et al. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med 1998; 157: 1726-1733.
7. Peloquin CA, Nitta AT, Burman WJ, et al. Low anti-tuberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30: 919-925.
8. Choudri S H, Hawken M, Gathua S, et al. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. Clin Infect Dis 1997; 25: 104-111.
9. Kimerling M E, Philips P, Patterson P, et al. Low serum antimycobacterial drug levels in non-HIV infected tuberculosis patients. Chest 1998; 113: 1178-1183.
10. Mcllleron H, Wash P, Burger A, et al. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6: 356-361.
11. Jamis-Dow C A, Katki A G, Collins J M, et al. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997; 27: 1015-1024.
12. 14C-rifapentine in healthy volunteers. Drug Metab Dispos 1998; 26: 732-738.
13. Leinweber F J. Possible physiological roles of carboxylic ester hydrolases. Drug Metab Rev 1987; 18: 379-439.
14. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978; 3: 108-127.
15. Keung A C, Eller M G, Weir S J. Single-dose pharmacokinetics of rifapentine in woman. J Pharmacokinet Biopharm 1998; 26: 75-85.
16. Taylor B, Smith P J. Does AIDS impair the absorption of antituberculosis agents? Int J Tuberc Lung Dis 1998; 2: 670-675.